Alain Patat

Functional Arterial Spin Labeling during a working memory task MRI at 3T. Comparison with BOLD fMRI

Isabelle Corouge, Christian Barillot, Elise Bannier, 2013 .

Residual Effects of Middle-of-the-Night Administration of Zaleplon and Zolpidem on Driving Ability, Memory Functions, and Psychomotor Performance

Joris C Verster, Alain Patat, M. Verbaten, 2002, Journal of clinical psychopharmacology.

Effects of a new slow release formulation of caffeine on EEG, psychomotor and cognitive functions in sleep‐deprived subjects

Alain Patat, P. Rosenzweig, A. Patat, 2000, Human psychopharmacology.

Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening

Neil Stanley, Alain Patat, I. Hindmarch, 2001, Human psychopharmacology.

Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test.

Joris C Verster, Berend Olivier, Alain Patat, 2006, Current drug safety.

Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.

Dominique Larrey, Stefan Zeuzem, Alain Patat, 2011, Journal of hepatology.

Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.

Dominique Larrey, Stefan Zeuzem, Alain Patat, 2011, The Journal of infectious diseases.

Pharmacodynamics and Pharmacokinetics of Two Dose Regimens of Befloxatone, a New Reversible and Selective Monoamine Oxidase Inhibitor, at Steady State in Healthy Volunteers

Olivier Curet, Alain Patat, P. Rosenzweig, 1996, Journal of clinical pharmacology.